KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules

Cancer Research

Volumn 59, Issue 12, 1999, Pages 2931-2938

  Soga, Shiro ^a   Neckers, Leonard M ^b   Schulte, Theodor W ^b   Shiotsu, Yukimasa ^a   Akasaka, Kazuhito ^a   Narumi, Hiroaki ^a   Agatsuma, Tsutomu ^a   Ikuina, Yoji ^a   Murakata, Chikara ^a   Tamaoki, Tatsuya ^a   Akinaga, Shiro ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHAPERONE; HEAT SHOCK PROTEIN 60; KF 29163; OXIME DERIVATIVE; RADICICOL; RADICICOL DERIVATIVE; RADICOCOL 6 OXIME; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG PROTEIN BINDING; FEMALE; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BENZOQUINONES; CELL LINE; DRUG SCREENING ASSAYS, ANTITUMOR; GENES, RAS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; LACTONES; MACROLIDES; MICE; MICE, INBRED BALB C; MICE, NUDE; ONCOGENE PROTEIN PP60(V-SRC); QUINONES; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 0033564430     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Delmotte, P., and Delmotte-Plaquee, J. A new antifungal substance of fungal origin. Nature (Lond.), 171: 344, 1953.
2. Kwon, H. J., Yoshida, M., Abe, K., Horinouchi, S., and Beppu, T. Radicicol, an agent inducing the reversal of transformed phenotypes of Src-transformed fibcoblasts. Biosci. Biotechnol. Biochem., 56; 538-539, 1992.
3. Zhao, J. F., Nakano, H., and Sharma, S. V. Suppression of RAS and MOS transformation by radicicol. Oncogene, 11: 161-173, 1995.
4. Kwon, H. J., Yoshida, M., Nagaoka, R., Obinata, T., Beppu, T., and Horinouti, S. Suppression of morphological transformation by radicicol is accompanied by enhanced gelsolin expression. Oncogene, 15: 2625-2631, 1997.
5. v-src protein kinase both in vivo and in vitro by radicicol. Cancer Res., 52: 6926-6930, 1992.
6. Pillay, I., Nakano, H., and Sharma, S. V. Radicicol inhibits tyrosine phosphorylation of the mitotic Src substrate Sam68 and retards subsequent exit from Src-transformed cells. Cell Growth Differ., 7: 1487-1499, 1996.
7. Soga, S., Kozawa, T., Narumi, H., Akinaga, S., Irie, K., Matsumoto, K., Sharma, S. V., Nakano, H., Mizukami, T., and Hara, M. Radicicol leads to selective depletion of Raf kinase and disrupts K-Ras-activated aberrant signaling pathway. J. Biol. Chem., 273: 822-828, 1998.
8. Schulte, T. W., Blagosklonny, M. V., Ingui, C., and Neckers, L. M. Disruption of the Raf-1-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association. J. Biol. Chem., 270: 24585-24588, 1995.
9. Schulte, T. W., Blagosklonny, M. V., Romanova, L., Mushinski, J. F., Monia, B. P., Johnston, J. F., Nguyen, P., Trepel, J., and Neckers, L. M. Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway. Mol. Cell. Biol., 16: 5839-5845, 1996.
10. Stancato, L. F., Silverstein, A. M., Owens-Grillo, J. K., Chow, Y. H., Jove, R., and Pratt, W. B. The hsp90-binding antibiotic geldanamycin decreases Raf levels and epidermal growth factor signaling without disrupting formation of signaling complexes or reducing the specific enzymatic activity of raf kinase. J. Biol. Chem., 272: 4013-4020, 1997.
11. Stebbins, C. E., Russo, A. A., Schneider, C., Rosen, N., Hartl, F. U., and Pavletich, N. P. Crystal structure of an hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell, 89: 239-250, 1997.
12. Grenert, J. P., Sullivan, W. P., Fadden, P., Haystead, T. A. J. Clark, J., Mimnaugh, E., Krutzsch, H., Ochel, H-J., Schulte, T. W., Sausville, E., Neckers, L. M., and Toft, D. O. The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. J. Biol. Chem., 272: 23843-23850, 1997.
13. Schulte, T. W., Akinaga, S., Soga, S., Sullivan, W., Stensgard, B., Toft, D., and Neckers, L. M. Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin Cell Stress Chaperones, 3: 100-108, 1998.
14. Sharma, S. V., Agatsuma, T., and Nakano, H. Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol. Oncogene, 16: 2639-2645, 1998.
15. Pratt, W. B., and Toft, D. O. Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr. Rev., 18: 306-360, 1997.
16. Segnitz, B., and Gehring, U. The function of steroid hormone receptors is inhibited by the hsp90-specific compound geldanamycin. J. Biol. Chem., 272: 18694-18701, 1997.
17. Murakami, Y., Mizuno, S., and Uehara, Y. Accelerated degradation of 160 kDa epidermal growth factor (EGF) receptor precursor by the tyrosine kinase inhibitor herbimycin A in the endoplasmic reticulum of A431 human epidermoid carcinoma cells. Biochem. J., 301: 63-68, 1994.
18. erbB2. J. Biol. Chem., 271: 4974-4977, 1996.
19. Hartmann, F., Horak, E. M., Cho, C., Lupu, R., Bolen, J. B., Stetler-Stevenson, M. A., Pfreundschuh, M., Waldmann, T. A., and Horak, I. D. Effects of the tyrosine-kinase inhibitor geldanamycin on ligand-induced Her-2/Neu activation, receptor expression and proliferation of Her-2-positive malignant cell lines. Int. J. Cancer, 70: 221-229, 1997.
20. v-src kinase. Proc. Natl. Acad. Sci. USA. 90: 7074-7078, 1993.
21. Hartson, S. D., and Matts, R. L. Association of Hsp90 with cellular Src-family kinases in a cell-free system correlates with altered kinase structure and function. Biochemistry, 33: 8912-8920, 1994.
22. v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl. Acad. Sci. USA, 91: 8324-8328, 1994.
23. Stancato, L. F., Chow, Y. H., Hutchison, K. A., Perdew, G. H., Jove, R., and Pratt, W. B. Raf exists in a native heterocomplex with hsp90 and p50 that can be reconstituted in a cell-free system. J. Biol. Chem., 268: 21711-21716, 1993.
24. cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilize Cdk4. Genes Dev., 10: 1491-1502, 1996.
25. Blagosklonny, M. V., Toretsky, J., and Neckers, L. Geldanamycin selectively destabilizes and conformationally alters mutated p53. Oncogene, 11: 933-939, 1995.
26. Blagosklonny, M. V., Toretsky, J., Bohen. S., and Neckers, L. Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90. Proc. Natl. Acad. Sci. USA, 93: 8379-8383, 1996.
27. Whitsell, L., Sutphin, P., An, W. G., Schulte, T., Blagosklonny, M. V., and Neckers, L. Geldanamycin-stimulated destabilization of mutated p53 is mediated by the proteosome in vivo. Oncogene, 14: 2809-2816, 1997.
28. Whitesell, L., Sutphin, P. D., Pulcini, E. J., Martinez, J. D., and Cook, P. H. The physical association of multiple molecular chaperone proteins with mutant p53 is altered by geldanamycin, an hsp90-binding agent. Mol. Cell. Biol., 18: 1517-1524, 1998.
29. erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives. J. Med. Chem., 38: 3806-3812, 1995.
30. Schnur, R. C., Corman, M. L., Gallaschun, R. J,. Cooper, B. A., Dee, M. F., Doty, J. L., Muzzi, M. L., DiOrio, C. I., Barbacci, E. G., Millar, P. E., Pollack, V. A., Savage, D. M., Sloan, D. E., Pustilnik, L. R., Moyer, J. D., and Moyer, M. P. erbB-2 oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action, and structure-activity relationships. J. Med. Chem., 38: 3813-3820, 1995.
31. Paine-Murrieta, G. D., Cook, P., Taylor, C. W., and Whitesell, L. Novel anti-breast cancer activity of benzoquinone ansamycines. Proc. Am. Assoc. Cancer Res., 39: 175, 1998.
32. Schulte, T. W., and Neckers, L. M. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother. Pharmacol., 42: 273-279, 1998.
33. Alley, M. C., Scudiero, D. A., Monks, A., Czerwinski, M., Shoemaker, R. H., and Boyd, M. R. Validation of an automated microculture tetrazolium assay (MTA) to assess growth and drug sensitivity of human tumor cell lines. Proc. Am. Assoc. Cancer Res., 27: 389, 1986.
34. Alley, M. C., Scudiero, D. A., Monks, A., Hursey. M. L., Czerwinski, M. J., Fine, D. L., Abbott, B. J., Mayo, J. G., Shoemaker, R. H., and Boyd, M. R. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res., 48: 589-601, 1988.
35. Geran, R. I., Greenberg, N. H., MacDonald, M. M., Schumacher, A. M., and Abbott, B. J. Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother. Rep Part 3, 3: 1-103, 1972.
36. Supko, J. G., Hickman, R. L., Grever, M. R., and Malspeis, L. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother. Pharmacol., 36: 305-315, 1995.
37. Page, J., Heath, J., Fulton, R., Yalkowsky, E., Tabibi, E., Tomaszewski, J., Smith, A., and Rodman, L. Comparison of geldanamycin (NSC-122750) and 17-allylaminogeldanamycin (NSC-330507D) toxicity in rats. Proc. Am. Assoc. Cancer Res., 38: 308, 1997.
38. Lebeau, J., Le, Chalony, C., Prosperi, M. T., and Goubin, G. Constitutive overexpression of 89kDa heat shock protein gene in the HBL100 human mammary cell line converted to a tumorigenic phenotype by the EJ/T24 Harvey-ras oncogene. Oncogene, 6: 1125-1132, 1991.
39. Legagneux, V., Mezger, V., Quelard, C., Barnier, J. V., Bensaude, O., and Morange, M. High constitutive transcription of HSP86 gene in murine embryonal carcinoma cells. Differentiation, 41: 42-48, 1989.
40. Ferrarini, M., Heltai, S., Zocchi, M. R., and Rugarli, C. Unusual expression and localization of heat-shock proteins in human tumor cells. Int. J. Cancer, 51 :613-619, 1992.
41. Gabai, V. L., Mosina, V. A., Budagova, K. R., and Kabakov, A. E. Spontaneous overexpression of heat-shock protein in Ehrlich ascites carcinoma cells during in vivo growth. Biochem. Mol. Int., 35: 95-102, 1995.
42. Yufu, Y., Nishimura, J., and Nawata, H. High constitutive expression of heat shock protein 90α in human acute leukemia cells. Leuk. Res., 16: 597-605, 1992.
43. Chant, I. D., Rose, P. E., and Morris, A. G. Analysis of heat-shock protein expression in myeloid leukemia cells by flow cytometry. Br. J. Haematol., 90: 163-168, 1995.
44. Ehrenfried, J. A., Herron, B. E., Townsend, C. M., Jr., and Evers, B. M. Heat shock proteins are differentially expressed in human gastrointestinal cancers. Surg. Oncol., 4: 197-203, 1995.
45. Mileo, A. M., Fanuele, M., Battaglia, F., Scambia, G., Benedetti-Panici, P., Mancuso, S., and Ferrini, U. Selective over-expression of mRNA coding for 90 kDa stressprotein in human ovarian cancer. Anticancer Res., 10; 903-906, 1990.
46. Gress, T. M., Muller-Pillasch, F., Weber, C., Lerch, M. M., Friess, H., Buchler, M., Beger, H. G., and Adler, G. Differential expression of heat shock proteins in pancreatic carcinoma. Cancer Res., 54: 547-551, 1994.
47. Nanbu, K., Konishi, I., Komatsu, T., Mandai, M., Yamamoto, S., Kuroda, H., Koshiyama, M., and Mori, T. Expression of heat shock proteins HSP70 and HSP90 in endometrial carcinomas. Correlation with clinicopathology, sex steroid receptor status, and p53 protein expression. Cancer (Phila), 77: 330-338, 1996.
48. Menoret, A., Meflah, K., and Le Pendu, J. Expression of the 100-kda gulucose-regulated protein (GRP100/endoplasmin) is associated with tumorigenicity in a model of rat colon adenocarcinoma. Int. J. Cancer, 56: 400-405, 1994.
49. Cai, J-W., Henderson, B. W., Shen, J-W., and Subjeck, J. R. Induction of glucose regulated proteins during growth of a murine tumor. J. Cell Physiol., 154: 229-237, 1993.
50. Jameel, A., Skilton, R. A., Campbell, T. A., Chander, S. K., Coombes, R. C., and Luqmani, Y. A. Clinical and biological significance of HSP89α in human breast cancer. Int. J. Cancer, 50; 409-415, 1992.
51. Franzen, B., Linder, S., Alaiya, A. A., Eriksson, E., Fujioka, K., Bergman, A. C., Jornvall, H., and Auer, G. Analysis of polypeptide expression in benign and malignant human breast lesions. Electrophoresis, 18: 582-587, 1997.
52. Haverty, A. A., Harmey, J. H., Redmond, H. P., and Bouchier-Hayes, D. J. Interleukin-6 upregulates gp96 expression in breast cancer. J. Surg. Res., 69: 145-149, 1997.
53. Jameel, A., Law, M., Coombes, R. C., and Luqmani, Y. A. Significance of heat shock protein 90 as prognostic indicator in breast cancer. Int. J. Oncol., 2: 1075-1080, 1993.
54. Yano, M., Naito, Z., Tanaka, S., and Asano, G. Expression and roles of heat shock proteins in human breast cancer. Jpn. J. Cancer Res., 87: 908-915, 1996.
55. Smith, D. F., Whitesell, L., Nair, S. C., Chen, S., Prapapanich, V., and Rimerman, R. A. Progesterone receptor structure and function altered by geldanamycin, an hsp90-binding agent. Mol. Cell. Biol., 15: 6804-6812, 1995.
56. Oikawa, T., Ito, H., Ashino, H., Toi, M., Tominaga, T., Morita, I., and Murota, S. Radicicol, a microbial cell differentiation modulator, inhibits in vivo angiogenesis. Eur. J. Pharmacol., 241: 221-227, 1993.
57. Chanmugam, P., Feng, L., Liou, S., Jang, B. C., Boudreau, M., Yu, G., Lee, J. H., Kwon, H. J., Beppu, T., Yoshida, M., Xia, Y., Wilson, C. B., and Hwang, D. Radicicol, a protein tyrosine kinase inhibitor, suppresses the expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide and in experimental glomerulonephritis. J. Biol. Chem., 270: 5418-5426, 1995.
58. Hwang, D., Fischer, N. H., Jang, B. C., Tak, H., Kim, J. K., and Lee, W. Inhibition of the expression of indudble cyclooxygenase and proinflammatory cytokines by sesquiterpene lactones in macrophages correlates with the inhibition of MAP kinases. Biochem. Biophys. Res. Commun., 226: 810-818, 1996.